
|Articles|April 4, 2016
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
3
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
4
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
5




